Cargando…
Metabolic Effects of Basal or Premixed Insulin Treatment in 5077 Insulin-Naïve Type 2 Diabetes Patients: Registry-Based Observational Study in Clinical Practice
INTRODUCTION: To investigate the clinical effects associated with premixed insulin (PM) and basal insulin [insulin NPH (NPH), insulin glargine (IG), insulin detemir (ID)], in insulin-naïve patients with type 2 diabetes in routine clinical care. MATERIALS AND METHODS: Cohort study based on data from...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065300/ https://www.ncbi.nlm.nih.gov/pubmed/24828137 http://dx.doi.org/10.1007/s13300-014-0068-9 |
_version_ | 1782322057960226816 |
---|---|
author | Eliasson, Björn Ekström, Nils Bruce Wirta, Sara Odén, Anders Fard, MirNabi Pirouzi Svensson, Ann-Marie |
author_facet | Eliasson, Björn Ekström, Nils Bruce Wirta, Sara Odén, Anders Fard, MirNabi Pirouzi Svensson, Ann-Marie |
author_sort | Eliasson, Björn |
collection | PubMed |
description | INTRODUCTION: To investigate the clinical effects associated with premixed insulin (PM) and basal insulin [insulin NPH (NPH), insulin glargine (IG), insulin detemir (ID)], in insulin-naïve patients with type 2 diabetes in routine clinical care. MATERIALS AND METHODS: Cohort study based on data from the Swedish National Diabetes Register, including 5,077 patients, resident in the Western region of Sweden. Patients were included between 1 July 2006 and 31 December 2009 and followed for 12 months. Changes in HbA1c, body mass index (BMI) and required insulin doses were compared between the different insulin types. Covariance adjustments were performed to adjust for differences between the groups. RESULTS: NPH, IG, ID and PM were all associated with significant reductions in HbA1c, mean ± standard deviation ranged between 6.6 ± 17.4 mmol/mol (IG) and 8.9 ± 17.7 mmol/mol (NPH), during the 12 months of follow-up. There were no statistically significant differences in the magnitude of HbA1c reduction between the insulin types. PM required 59% higher and ID 25% higher insulin doses to achieve a similar HbA1c reduction as NPH. PM was associated with a significantly greater increase in BMI compared with NPH (p = 0.016), while IG and ID did not differ significantly from NPH. The number of patients experiencing severe hypoglycemia was low, but highest in patients treated with PM (p = 0.023). CONCLUSIONS: NPH, IG, ID and PM were found to be equally effective in lowering HbA1c in insulin-naïve patients with type 2 diabetes in routine clinical care in Sweden. The effects on weight, dose and treatment persistence support the recommendation of NPH or IG as first and second choices in this group of patients requiring initiation of insulin treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-014-0068-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4065300 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-40653002014-06-25 Metabolic Effects of Basal or Premixed Insulin Treatment in 5077 Insulin-Naïve Type 2 Diabetes Patients: Registry-Based Observational Study in Clinical Practice Eliasson, Björn Ekström, Nils Bruce Wirta, Sara Odén, Anders Fard, MirNabi Pirouzi Svensson, Ann-Marie Diabetes Ther Original Research INTRODUCTION: To investigate the clinical effects associated with premixed insulin (PM) and basal insulin [insulin NPH (NPH), insulin glargine (IG), insulin detemir (ID)], in insulin-naïve patients with type 2 diabetes in routine clinical care. MATERIALS AND METHODS: Cohort study based on data from the Swedish National Diabetes Register, including 5,077 patients, resident in the Western region of Sweden. Patients were included between 1 July 2006 and 31 December 2009 and followed for 12 months. Changes in HbA1c, body mass index (BMI) and required insulin doses were compared between the different insulin types. Covariance adjustments were performed to adjust for differences between the groups. RESULTS: NPH, IG, ID and PM were all associated with significant reductions in HbA1c, mean ± standard deviation ranged between 6.6 ± 17.4 mmol/mol (IG) and 8.9 ± 17.7 mmol/mol (NPH), during the 12 months of follow-up. There were no statistically significant differences in the magnitude of HbA1c reduction between the insulin types. PM required 59% higher and ID 25% higher insulin doses to achieve a similar HbA1c reduction as NPH. PM was associated with a significantly greater increase in BMI compared with NPH (p = 0.016), while IG and ID did not differ significantly from NPH. The number of patients experiencing severe hypoglycemia was low, but highest in patients treated with PM (p = 0.023). CONCLUSIONS: NPH, IG, ID and PM were found to be equally effective in lowering HbA1c in insulin-naïve patients with type 2 diabetes in routine clinical care in Sweden. The effects on weight, dose and treatment persistence support the recommendation of NPH or IG as first and second choices in this group of patients requiring initiation of insulin treatment. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-014-0068-9) contains supplementary material, which is available to authorized users. Springer Healthcare 2014-05-15 2014-06 /pmc/articles/PMC4065300/ /pubmed/24828137 http://dx.doi.org/10.1007/s13300-014-0068-9 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Research Eliasson, Björn Ekström, Nils Bruce Wirta, Sara Odén, Anders Fard, MirNabi Pirouzi Svensson, Ann-Marie Metabolic Effects of Basal or Premixed Insulin Treatment in 5077 Insulin-Naïve Type 2 Diabetes Patients: Registry-Based Observational Study in Clinical Practice |
title | Metabolic Effects of Basal or Premixed Insulin Treatment in 5077 Insulin-Naïve Type 2 Diabetes Patients: Registry-Based Observational Study in Clinical Practice |
title_full | Metabolic Effects of Basal or Premixed Insulin Treatment in 5077 Insulin-Naïve Type 2 Diabetes Patients: Registry-Based Observational Study in Clinical Practice |
title_fullStr | Metabolic Effects of Basal or Premixed Insulin Treatment in 5077 Insulin-Naïve Type 2 Diabetes Patients: Registry-Based Observational Study in Clinical Practice |
title_full_unstemmed | Metabolic Effects of Basal or Premixed Insulin Treatment in 5077 Insulin-Naïve Type 2 Diabetes Patients: Registry-Based Observational Study in Clinical Practice |
title_short | Metabolic Effects of Basal or Premixed Insulin Treatment in 5077 Insulin-Naïve Type 2 Diabetes Patients: Registry-Based Observational Study in Clinical Practice |
title_sort | metabolic effects of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: registry-based observational study in clinical practice |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065300/ https://www.ncbi.nlm.nih.gov/pubmed/24828137 http://dx.doi.org/10.1007/s13300-014-0068-9 |
work_keys_str_mv | AT eliassonbjorn metaboliceffectsofbasalorpremixedinsulintreatmentin5077insulinnaivetype2diabetespatientsregistrybasedobservationalstudyinclinicalpractice AT ekstromnils metaboliceffectsofbasalorpremixedinsulintreatmentin5077insulinnaivetype2diabetespatientsregistrybasedobservationalstudyinclinicalpractice AT brucewirtasara metaboliceffectsofbasalorpremixedinsulintreatmentin5077insulinnaivetype2diabetespatientsregistrybasedobservationalstudyinclinicalpractice AT odenanders metaboliceffectsofbasalorpremixedinsulintreatmentin5077insulinnaivetype2diabetespatientsregistrybasedobservationalstudyinclinicalpractice AT fardmirnabipirouzi metaboliceffectsofbasalorpremixedinsulintreatmentin5077insulinnaivetype2diabetespatientsregistrybasedobservationalstudyinclinicalpractice AT svenssonannmarie metaboliceffectsofbasalorpremixedinsulintreatmentin5077insulinnaivetype2diabetespatientsregistrybasedobservationalstudyinclinicalpractice |